These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7697342)

  • 41. Methylation and p16: suppressing the suppressor.
    Little M; Wainwright B
    Nat Med; 1995 Jul; 1(7):633-4. PubMed ID: 7585141
    [No Abstract]   [Full Text] [Related]  

  • 42. Parsing Ink4a/Arf: "pure" p16-null mice.
    Sherr CJ
    Cell; 2001 Sep; 106(5):531-4. PubMed ID: 11551500
    [No Abstract]   [Full Text] [Related]  

  • 43. Cellular senescence and cancer.
    Barrett JC; Annab LA; Alcorta D; Preston G; Vojta P; Yin Y
    Cold Spring Harb Symp Quant Biol; 1994; 59():411-8. PubMed ID: 7587095
    [No Abstract]   [Full Text] [Related]  

  • 44. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
    Southgate J; Proffitt J; Roberts P; Smith B; Selby P
    Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.
    Koh J; Enders GH; Dynlacht BD; Harlow E
    Nature; 1995 Jun; 375(6531):506-10. PubMed ID: 7777061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.
    Khleif SN; DeGregori J; Yee CL; Otterson GA; Kaye FJ; Nevins JR; Howley PM
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4350-4. PubMed ID: 8633069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.
    Schreiber M; Muller WJ; Singh G; Graham FL
    Oncogene; 1999 Mar; 18(9):1663-76. PubMed ID: 10208428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
    Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Akagi M; Tahara H; Ishikawa T; Tahara E
    Jpn J Cancer Res; 1996 Aug; 87(8):824-30. PubMed ID: 8797888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A challenge to p16 gene as a major tumor suppressor.
    Marx J
    Science; 1994 Jun; 264(5167):1846. PubMed ID: 8009205
    [No Abstract]   [Full Text] [Related]  

  • 50. Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest.
    Hung KS; Hong CY; Lee J; Lin SK; Huang SC; Wang TM; Tse V; Sliverberg GD; Weng SC; Hsiao M
    Biochem Biophys Res Commun; 2000 Mar; 269(3):718-25. PubMed ID: 10720483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
    FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two tracks but one race? Cancer genetics.
    Sidransky D
    Curr Biol; 1996 May; 6(5):523-5. PubMed ID: 8805269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
    Zariwala M; Xiong Y
    Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
    Zhang S; Ramsay ES; Mock BA
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Hansson J; Hashemi J; Linder S; Platz A
    J Natl Cancer Inst; 2000 May; 92(9):758-60. PubMed ID: 10793118
    [No Abstract]   [Full Text] [Related]  

  • 56. Tumor suppressor INK4: quantitative structure-function analyses of p18INK4C as an inhibitor of cyclin-dependent kinase 4.
    Li J; Poi MJ; Qin D; Selby TL; Byeon IJ; Tsai MD
    Biochemistry; 2000 Feb; 39(4):649-57. PubMed ID: 10651629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor.
    Plath T; Detjen K; Welzel M; von Marschall Z; Murphy D; Schirner M; Wiedenmann B; Rosewicz S
    J Cell Biol; 2000 Sep; 150(6):1467-78. PubMed ID: 10995450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.
    Bartkova J; Thullberg M; Rajpert-De Meyts E; Skakkebaek NE; Bartek J
    Oncogene; 2000 Aug; 19(36):4146-50. PubMed ID: 10962575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cyclin-dependent kinase inhibitors in mammal cells].
    Jiang H; Wang YC
    Sheng Li Ke Xue Jin Zhan; 1996 Apr; 27(2):107-12. PubMed ID: 9592231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tribulations of the p16/MTS1/CDKN2 tumor gene suppressor: a continuing saga].
    Larsen CJ
    Bull Cancer; 1997 Apr; 84(4):427-30. PubMed ID: 9238169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.